SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

10 Nov 2016 07:00

RNS Number : 8050O
Devro PLC
10 November 2016
 

This announcement contains inside information

10 November 2016

 

Devro plc

 

Trading Update

 

Devro plc ("the Group"), one of the world's leading manufacturers of collagen products for the food industry, today issues a trading update for the period 1 July 2016 to the current date ("the period").

Trading summary for the period and 2016 outlook

Sales volume trends were broadly similar to those experienced in the first half, enhanced by improvements in Russia and South East Asia, but impacted by further reductions in Latin America due to the previously highlighted issues, which are being addressed, related to the transformation of our global manufacturing footprint. Combined, these factors have had an adverse impact on margins, offset by further benefits from lower input costs and foreign exchange. As a result, the Board's full year expectations for underlying operating profit* remain unchanged.

Our new factories in the US and China are now integrated into the Group's manufacturing base, completing the transformation of our global manufacturing footprint. As expected, in the second half £8 million of exceptional costs related to these capital investment projects have been incurred, including £1 million of additional foreign exchange movements. There will be no further exceptional costs related to these capital investment projects.

2017 and beyond

Based on current trends, sales volumes in 2017 are now expected to be approximately 10% lower than previously anticipated, which will result in an under-utilisation of available capacity. Actions are being taken to rebalance the use of capacity across our global manufacturing base. The under-utilisation is expected to have a further adverse impact on margins.

The Board has decided to accelerate and implement more extensively the next stage of the Group's strategic development, focusing on growing sales through improved commercial capabilities, introducing the next generation of differentiated products, and further improving manufacturing efficiencies to reduce unit costs. This improvement project will deliver a fundamentally more competitive position. The benefits will offset the effects of the lower volumes, partially in 2017 and fully in 2018. 

Consequently, the Board now expects underlying operating profit* for 2017 to be lower than previous expectations.

There will be additional costs and capital expenditure associated with the improvement project. Given the nature and scale of the planned actions, these costs will be charged as exceptional items, of which approximately £3 million is expected to be incurred in the final quarter of 2016.

Devro's markets remain attractive. With completion of the capital investment projects the Group now has an excellent manufacturing base and, with the benefits resulting from the improvement project, the Board considers the Group to be well positioned to grow revenue and profits over the long term.

* Underlying operating profit is defined as operating profit before exceptional items

 

ENDS

 

 

Contacts:

 

Devro plc

Peter Page

Chief Executive

Tel: 020 7182 4960

Rutger Helbing

Group Finance Director

Tel: 020 7182 4960

 

FTI Consulting

Richard Mountain / Nick Hasell

Tel: 020 3727 1340

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFSIEFUFMSEDF
Date   Source Headline
24th Mar 20174:00 pmRNS2016 Annual Report
15th Mar 20175:14 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSNotification of Board changes
6th Mar 20177:00 amRNSFinal Results
21st Feb 20172:43 pmRNSHolding(s) in Company
25th Jan 20174:36 pmRNSHolding(s) in Company
11th Jan 20177:00 amRNSYear End Trading Update
21st Dec 20167:00 amRNSAppointment of Non-Executive Director
8th Dec 20164:52 pmRNSDirector/PDMR Shareholding
8th Dec 20164:15 pmRNSDirector/PDMR Shareholding
7th Dec 20164:32 pmRNSDirector/PDMR Shareholding
25th Nov 20163:01 pmRNSDirector/PDMR Shareholding
24th Nov 20163:14 pmRNSBlock listing Interim Review
23rd Nov 20161:32 pmRNSDirector/PDMR Shareholding
14th Nov 201611:36 amRNSDirector/PDMR Shareholding
10th Nov 20164:12 pmRNSDirector/PDMR Shareholding
10th Nov 20164:07 pmRNSDirector/PDMR Shareholding
10th Nov 201610:51 amRNSDirector/PDMR Shareholding
10th Nov 20167:00 amRNSTrading Update
21st Sep 20165:05 pmRNSHolding(s) in Company
18th Aug 20162:24 pmRNSDirector/PDMR Shareholding
18th Aug 20162:23 pmRNSDirector/PDMR Shareholding
11th Aug 201610:41 amRNSHolding(s) in Company
8th Aug 20162:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20167:00 amRNSHalf-year Report
21st Jul 20163:53 pmRNSHolding(s) in Company
30th Jun 20167:00 amRNSTotal Voting Rights and Share Capital
23rd Jun 20163:16 pmRNSDirector/PDMR Shareholding
10th Jun 201610:18 amRNSHolding(s) in Company
25th May 20165:38 pmRNSHolding(s) in Company
24th May 201611:53 amRNSBlock listing Interim Review
23rd May 20163:33 pmRNSDirector/PDMR Shareholding
13th May 20163:33 pmRNSDirector Declaration
5th May 20164:23 pmRNSHolding(s) in Company
28th Apr 20163:54 pmRNSDirector/PDMR Shareholding
27th Apr 20164:45 pmRNSResults of Annual General Meeting
27th Apr 20167:00 amRNSTrading Update
8th Apr 20163:33 pmRNSNotification of Transactions of Directors
30th Mar 20167:00 amRNSAnnual Financial Report
29th Mar 201612:35 pmRNSFurther re: Group Finance Director Retirement
23rd Mar 201612:52 pmRNSNotification of Transactions of Directors
1st Mar 20167:00 amRNSFinal Results
17th Feb 201610:13 amRNSHolding(s) in Company
9th Feb 201612:56 pmRNSHolding(s) in Company
9th Dec 20157:00 amRNSGroup Finance Director
27th Nov 20154:30 pmRNSNotification of Transactions of Directors
24th Nov 20158:23 amRNSBlock Listing Six Monthly Return
17th Nov 20157:01 amRNSGroup Finance Director Retirement
17th Nov 20157:00 amRNSTrading update
21st Oct 20157:00 amRNSNotice of trading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.